Remodeling Tumor Macrophages With CD47-Targeted Bispecific Antibodies

Time: 1:30 pm
day: Pre-Conference Focus Day

Details:

  • Addressing a ubiquitous target with bispecifc Abs
  • Modulating tumor immune microenvironment by targeted CD47 blockade
  • NI-1801, a Phase I ready CD47xMesothelin biAb for solid cancer

Speakers: